Seed · Healthtech · Barcelona, Spain · Founded 2021 · 11–15 employees
MiMARK is developing innovative in vitro diagnostic solutions for gynecological diseases, focusing on endometrial cancer diagnosis. The company uses gynecological fluids as the next step in liquid biopsy in gynecology, offering a less invasive approach than traditional methods. Their flagship product WomEC is an in vitro diagnostic test for endometrial cancer with targeted sensitivity of 97% and specificity of 78%. They recently raised €4.22 million in seed funding and have completed a national study across 28 sites in Spain with nearly 2,000 patients.
No open roles listed right now.